Summary In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-a2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.
Treatment of advanced multiple myeloma (MM) usually employs combination chemotherapy (Buzaid and Durie, 1988) . We used either cyclophosphamide (CTX) or epirubicin (EPI), both associated with recombinant interferon (IFN) and prednisone (P), as third-line therapy, with the expectancy that haematological toxicity would be low and the therapy feasible on an outpatient basis. All patients came from Protocol MM87 (Riccardi et al., 1994) , where they were treated, as first-line therapy, either with melphalan and prednisone (MPH -P) or peptichemio (PTC), vincristine (VCR) and P. As second-line therapy, patients resistant to or relapsed following one combination were crossed to the other combination.
The choice of salvage CTX came from the fact that MPHresistant MM patients may respond to this drug (Bergsagel et al., 1972; Lenhard et al., 1984) . The use of EPI was justified by the response of advanced patients to the several combination chemotherapies including anthracycline (Alberts et al., 1976; Finnish Leukaemia Group, 1990 ).
Materials and methods
Between January 1989 and December 1993, 83 consecutive patients (Table I ) entered a third-line, prospective, multicentre, randomised protocol (Protocol MM87/01) for advanced MM. Patients were primarily resistant to or relapsed following a response to first-and second-line therapies of Protocol MM87 (i.e. to MPH-P and PTC-VCR-P) (Riccardi et al., 1994) .
Randomisation was between EPI (70 mg m-2) and CTX (600 mg m-2) given by i.v. infusion on day 1 every 3 weeks for 3 courses. Both cytostatics were combined with P (2mgkg-l day-', days 1-4 and 11-15) (Riccardi et al., 1994) . To define the drug toxicity blood counts were performed twice in the interval between courses.
The statistical evaluation of the differences in response rate and duration of response (from the end of successful induction therapy until relapse) and of survival (from randomisation to death) are described elsewhere (Riccardi et al., 1994) .
Results
In both EPI -P-IFN and CTX-P-IFN arms, patients were similar for the main clinical characteristics (Table I) , and more of them had received MPH-P as a first-line therapy, with similar response rate.
Patients who relapsed following a response to first-line therapy had received a median of 19.8 (range 12-33) and of 17.1 (10-28) courses of MPH-P and PTC-VCR-P respectively. In patients who were primarily resistant, the corresponding figures were 12.1 (10-16) and 12.4 (8-16 Table I Main clinical characteristics of patients with advanced multiple myeloma who were randomised to be treated, as third-line therapy, with the combination of epirubicin, prednisone and recombinant interferon-a2b (EPI-P-IFN) or with the combination of cyclophosphamide, prednisone and recombinant interferon-a2b (CTX-P-IFN) Table I) response could be established and were considered as nonresponders. Thirteen patients were not evaluated for refusal to continue treatment (four patients), insufficient data or lost to follow-up (nine patients).
The overall response rate was 43%, without statistical difference between the EPI-P-IFN (38%) and the CTX-P-IFN (48%) arm.
The response rate was similar in patients firstly treated with MPH-P and with PTC-VCR-P.
More responsive patients had WHO/ECOG performance status ameliorated (Table III) , in a median time of 7 (range: 6-10) weeks in the EPI-P-IFN and of 10 (range: 6-12) weeks in the CTX-P-IFN arm.
Duration of response and of survival
The overall median duration of response was 5.9 months. It was similar in the EPI-P-IFN (5.5 months) and in the CTX-P-IFN (6.4 months) arm. Overall median survival was 14.1 months. It was similar in the EPI-P-IFN (13.9 months) and in the CTX-P-IFN (14.3 months) arm (Figure 1 ), as well as in patients who were primarily resistant to first-line therapy (15.0 months) and in those who relapsed following a response (13.4 months).
Toxicity
Overall haematological toxicity was low and 88% of courses were administered on an outpatient basis. Febrile neutropenia occurred in 12% and grade Ill anaemia and thrombocytopenia in 7% and 5% of patients. These figures were somewhat but not significantly greater in the EPI-P-IFN than in the CTX-P-IFN arm (15%, 10% and 7% vs 6%, 4% and 2% respectively).
Grade 2-3 alopecia was distinctly more frequent in the EPI-P-IFN than in the CIX-P-IFN (55% vs 9%, P<0.01). Grade 2 emesis occurred in 20% and 9% (Pvalue not significant) of patients respectively. Stomatitis was unusual.
Four patients in both arms stopped IFN for grade 3 chills and/or fever, uncontrolled by acetaminophen premedications. There was no cardiac damag attributable to EPI and no gastrointestinal, psychiatric or metabolic damage attributable to steroids.
In this randomised study, patients with MM who were resistant to or relapsed following MPH-P and PTC-VCR-P achieved similar clinical benefit from being treated with EPI-P-IFN or CTX-P-IFN. In fact, response rate, changes in WHO/ECOG status and response and survival duration were similar with the two regimens.
These results are in keeping with published data on the value of CTX and anthracyclines for advanced MM. Used alone, CTX was effective in a number (Bersagel et al., 1972; Brandes and Israels, 1987) , although not in all (Presant and Klahr, 1978; Maclennan and Cuzick, 1985) , non-randomised investigations. At present it is incorporated into regimens for refractory disease (Kyle et al., 1975; Steinke et al., 1985) . Anthracyclines have not been used as a single agent. However, anthracycline-containing rgmens are effective in both relapsed (Alexanian and Deeicer, 1984; Barlogie and Alexanian, 1987; Presant and Klahr, 1978) and primarily resistant (Cornelissen et al., 1994) patients. The clinical role of IFN and steroids in favouring the effectiveness of both EPI and CTX cannot be established in this study.
As expected, haematological toxicity was low, nonhaematological toxicity was acceptable and most patients were treated on an outpatient basis.
The overall 14.1 month median survival compares well with the median survivals of 5-22 months (the weighted median is about 10 months) reported in small nonrandomised studies on salvage therapy in MM (Bonnet et al., 1984; Lenhard et al., 1984; Steinke et al., 1985; Alexanian et al., 1986; Forgeson et al., 1988; Finnish Leukaemia Group, 1990; Friedenberg et al., 1991; Gimsing et al., 1991; Cornelissen et al., 1994) . These usually employed more cytotoxic drug combinations and often required hospitalisation. Median survival is also not better in young patients with advanced disease following autologous bone marrow (BM) or peripheral blood stem cell transplantation (Barlogie et al., 1986; Fermand et al., 1989 ).
In conclusion, it seems clinically acceptable to treat advanced MM with poorly myelosuppressive regimens based on medium doses of CIX or anthracyclines.
The following centres also participated in this study: Servizio di Oncologia, Ospedale S. Anna, 22100 Como (Dr C Epifani, Dr 
